7 research outputs found
Real-time measurement of ICD lead motion during stereotactic body radiotherapy of ventricular tachycardia
Background: Here we aimed to evaluate the respiratory and cardiac-induced motion of a ICD lead used as surrogate in the heart during stereotactic body radiotherapy (SBRT) of ventricular tachycardia (VT). Data provides insight regarding motion and motion variations during treatment.
Materials and methods: We analyzed the log files of surrogate motion during SBRT of ventricular tachycardia performed in 20 patients. Evaluated parameters included the ICD lead motion amplitudes; intrafraction amplitude variability; correlation error between the ICD lead and external markers; and margin expansion in the superior-inferior (SI), latero-lateral (LL), and anterior-posterior (AP) directions to cover 90% or 95% of all amplitudes.
Results: In the SI, LL, and AP directions, respectively, the mean motion amplitudes were 5.0 +/- 2.6, 3.4. +/- 1.9, and 3.1 +/- 1.6 mm. The mean intrafraction amplitude variability was 2.6 +/- 0.9, 1.9 +/- 1.3, and 1.6 +/- 0.8 mm in the SI, LL, and AP directions, respectively. The margins required to cover 95% of ICD lead motion amplitudes were 9.5, 6.7, and 5.5 mm in the SI, LL, and AP directions, respectively. The mean correlation error was 2.2 +/- 0.9 mm.
Conclusions: Data from online tracking indicated motion irregularities and correlation errors, necessitating an increased CTV-PTV margin of 3 mm. In 35% of cases, the motion variability exceeded 3 mm in one or more directions. We recommend verifying the correlation between CTV and surrogate individually for every patient, especially for targets with posterobasal localization where we observed the highest difference between the lead and CTV motion.Web of Science26113712
Real-time measurement of ICD lead motion during stereotactic body radiotherapy of ventricular tachycardia
Background: Here we aimed to evaluate the respiratory and cardiac-induced motion of a ICD lead used as surrogate in the heart during stereotactic body radiotherapy (SBRT) of ventricular tachycardia (VT). Data provides insight regarding motion and motion variations during treatment.
Materials and methods: We analyzed the log files of surrogate motion during SBRT of ventricular tachycardia performed in 20 patients. Evaluated parameters included the ICD lead motion amplitudes; intrafraction amplitude variability; correlation error between the ICD lead and external markers; and margin expansion in the superior-inferior (SI), latero-lateral (LL), and anterior-posterior (AP) directions to cover 90% or 95% of all amplitudes.
Results: In the SI, LL, and AP directions, respectively, the mean motion amplitudes were 5.0 ± 2.6, 3.4. ± 1.9, and 3.1 ± 1.6 mm. The mean intrafraction amplitude variability was 2.6 ± 0.9, 1.9 ± 1.3, and 1.6 ± 0.8 mm in the SI, LL, and AP directions, respectively. The margins required to cover 95% of ICD lead motion amplitudes were 9.5, 6.7, and 5.5 mm in the SI, LL, and AP directions, respectively. The mean correlation error was 2.2 ± 0.9 mm.
Conclusions: Data from online tracking indicated motion irregularities and correlation errors, necessitating an increased CTV-PTV margin of 3 mm. In 35% of cases, the motion variability exceeded 3 mm in one or more directions. We recommend verifying the correlation between CTV and surrogate individually for every patient, especially for targets with posterobasal localization where we observed the highest difference between the lead and CTV motion
Cardiac Radiosurgery for Malignant Ventricular Tachycardia
Abstract Ventricular tachycardia is a frequent cause of mortality after myocardial infarction. Current treatment includes the implantation of cardioverter defibrillators and adjunctive therapies such as catheter ablation or cardiac surgery. In patients where standard treatment fails, preclinical data showed that radiosurgery ablation of the ectopic substrate might be a viable option. Authors present a case report of cardiac radiosurgery in a patient with malignant ventricular tachycardia. Stereotactic radiosurgery system CyberKnife was used; the applied dose was 25 Gy in one fraction. Within the follow-up period of 120 days, no signs of toxicity were noted no episode of malignant arrhythmia has been detected. This case report demonstrates that stereotactic radiosurgery of recurrent ventricular tachycardia after inefficient catheter ablation might be a viable option for patients unsuitable for cardiosurgical intervention. Further research on this topic is highly warranted
Early ganglion stellate blockade as part of two-step treatment algorithm suppresses electrical storm and need for intubation
Background: For the treatment of patients with electrical storm (ES), we established a two-step algo rithm comprising standard anti-arrhythmic measures and early ultrasound-guided stellate ganglion
blockade (SGB). In this single-center study, we evaluated the short-term efficacy of the algorithm and
tested the hypothesis that early SGB might prevent the need for intubations.
Methods: Overall, we analyzed data for 70 ES events in 59 patients requiring SGB (mean age
67.7 ± 12.4 years, 80% males, left ventricular ejection fraction 30.0% ± 9.1%), all with implantable
cardioverter-defibrillators (ICDs).
Results: The mean time from ES onset to SGB was 13.2 ± 12.3 hours. Percentage and mean absolute
reduction in shocks at 48 hours after SGB reached 86.8% ( 6.3 shocks), and anti-tachycardiac pacing
(ATP) declined by 65.9% ( 51.1 ATPs; all P < 0.001). Patients with the highest sustained ventricular
arrhythmia (VA) burden (shocks 10/48 h; ATPs 10e99/48 h and 100/48 h) experienced the highest
percentage decrease in ICD therapy (shocks 99.1%; ATPs 92.1% and 100.0%, respectively). For clinical
response by defined criteria and two outcome periods (1/no sustained VA 48 hours post SGB, and 2/no
ICD shock or <3 ATPs/day from day 3 to discharge/catheter ablation/day 8), 75.7% and 76.1% experienced
complete response, respectively. Catecholamine support, no/low-dose b-blocker therapy, polymorphic/
mixed-type VA, and baseline sinus rhythm versus atrial fibrillation were more frequent in patients
with early arrhythmia recurrence. Temporary Horner's syndrome occurred in 67.1%, and no other adverse
events were recorded. Intubation and general anesthesia during and after SGB were not needed.
Conclusion: The presented two-step algorithm for treating ES proved efficacious and safe. The results
support implementation of early SGB in routine ES management.Web of Science73352
The Effect of Diabetes-Associated Autoantigens on Cell Processes in Human PBMCs and Their Relevance to Autoimmune Diabetes Development
Type 1 Diabetes (T1D) is considered to be a T-helper- (Th-) 1 autoimmune disease; however, T1D pathogenesis likely involves many factors, and sufficient tools for autoreactive T cell detection for the study of this disease are currently lacking. In this study, using gene expression microarrays, we analysed the effect of diabetes-associated autoantigens on peripheral blood mononuclear cells (PBMCs) with the purpose of identifying (pre)diabetes-associated cell processes. Twelve patients with recent onset T1D, 18 first-degree relatives of the TD1 patients (DRL; 9/18 autoantibody positive), and 13 healthy controls (DV) were tested. PBMCs from these individuals were stimulated with a cocktail of diabetes-associated autoantigens (proinsulin, IA-2, and GAD65-derived peptides). After 72 hours, gene expression was evaluated by high-density gene microarray. The greatest number of functional differences was observed between relatives and controls (69 pathways), from which 15% of the pathways belonged to “immune response-related” processes. In the T1D versus controls comparison, more pathways (24%) were classified as “immune response-related.” Important pathways that were identified using data from the T1D versus controls comparison were pathways involving antigen presentation by MHCII, the activation of Th17 and Th22 responses, and cytoskeleton rearrangement-related processes. Genes involved in Th17 and TGF-beta cascades may represent novel, promising (pre)diabetes biomarkers